SOUTH SAN FRANCISCO, Calif.,
Oct. 26, 2021 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its third quarter 2021 financial
results after market close on Tuesday,
November 2, 2021. Rigel senior management will follow
the announcement with a live conference call and webcast at
4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial
results and give an update on the business.
Participants can access the live conference call by dialing
877-407-3088 (domestic) or 201-389-0927 (international). The
conference call and accompanying slides will also be webcast live
and can be accessed from the Investor Relations section of the
company's website at www.rigel.com. The webcast will be
archived and available for replay for 90 days after the call via
the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc., is a
biotechnology company dedicated to discovering, developing, and
providing novel small molecule drugs that significantly improve the
lives of patients with hematologic disorders, cancer, and rare
immune diseases. Rigel's pioneering research focuses on signaling
pathways that are critical to disease mechanisms. The company's
first FDA-approved product is TAVALISSE® (fostamatinib
disodium hexahydrate) tablets, the only oral spleen tyrosine kinase
(SYK) inhibitor for the treatment of adult patients with chronic
immune thrombocytopenia who have had an insufficient response to a
previous treatment. The product is also commercially available in
Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of
chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 clinical
trial (NCT03764618) for the treatment of warm autoimmune hemolytic
anemia (wAIHA)1; a Phase 3 clinical trial (NCT04629703)
for the treatment of hospitalized high-risk patients with
COVID-191; an NIH/NHLBI-sponsored Phase 3 clinical trial
(ACTIV-4 Host Tissue Trial, NCT04924660) for the treatment of
COVID-19 in hospitalized patients, and a Phase 2 clinical trial
(NCT04581954) for the treatment of COVID-19 being conducted by
Imperial College London.
Rigel's other clinical programs include its interleukin
receptor-associated kinase (IRAK) inhibitor program, and a
receptor-interacting serine/threonine-protein kinase (RIP1)
inhibitor program in clinical development with partner Eli Lilly
and Company. In addition, Rigel has product candidates in
development with partners AstraZeneca, BerGenBio ASA, and Daiichi
Sankyo.
For further information, visit www.rigel.com or follow us on
Twitter or LinkedIn.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Investor Contact:
Jodi Sievers
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2021-financial-results-and-business-update-301408145.html
SOURCE Rigel Pharmaceuticals, Inc.